Pyrazoloacridine — CAS 99009-20-8

Pyrazoloacridine (PZA / NSC 366140) is a novel antineoplastic agent that intercalates DNA and inhibits both topoisomerase I and topoisomerase II, producing cytotoxic effects in cancer cells. Mediocon Inc manufactures this high-purity API at its GMP-certified facility in Aurangabad, Maharashtra, India. It has been investigated clinically for treatment of solid tumors.

• Investigational treatment of solid tumors including ovarian and lung cancers
• Topoisomerase I and II inhibition in oncology research
• Combination chemotherapy protocols in clinical trials
• Research into novel DNA-intercalating anticancer strategies

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support